Abstract Submission
In anticipation of what promises to be a mass gathering and celebration of European basic, translational and clinical studies, we invite the European cancer community to submit abstracts before the regular abstract submission deadline of 29 April 2009.

New Late-Breaking Abstract Policy
To help ensure that the very latest findings are presented for the first time at ECCO 15 – ESMO 34, we are also pleased to report that we have revised our Late-Breaking abstract submission policy and increased the number of proffered paper slots and presidential sessions.

The Call for Late-Breaking abstracts will run from 22 July - 5 August 2009.

More
To view the Advance Programme, consult the abstract submission programme and discover the many reasons for making ECCO 15 – ESMO 34 your must attend meeting this year visit:

www.ecco-org.eu
(select ‘Congresses and conferences’ > ‘ECCO 15 – ESMO 34’).
A Strong Programme for EACR Members

In the year following an EACR Conference, members look to the ECCO congress to provide a programme that will meet their needs. EACR has been well represented in the Scientific Programme Committees for 2009 and we hope that you will find much to excite your interest.

With such a wide-ranging Conference Agenda it is an impossible task to identify everything in the programme of interest to EACR members. The listing that follows attempts to provide just a snapshot.

Speakers in the EACR Special Session including the Young Cancer Researcher of the Year Lecture will be announced through the EACR e-News Bulletin

Drug discovery in the p53 pathway
D. Lane (United Kingdom)

Old drugs vs new drugs and new levels of complexity
J.P. Armand (France)

Bioinformatics and gene discovery
K. Pienta (USA)

Targeting the cell cycle in cancer
M. Barbacid (Spain)

Insights into the cancer cell, stem cell interface through systems biology
F. Buchholz (Germany)

Oxygen sensing, HIF hydroxylases and new cancer targets
W.G. Kaelin, Jr (USA)

Multitasking by pVHL in tumour suppression
W. Krek (Switzerland)

Hypoxia-inducible factor 1 in cancer pathogenesis and therapy
G. Semenza (USA)

Hypoxia signalling, metabolism and cancer
J. Pouyssegur (France)

Hitting cancer where it hurts most: The RNAi strategy to discover synthetic lethal interactions in cancer
R. Beijersbergen (The Netherlands)

Synthetic Lethality - a novel strategy of cancer therapy
J. Downward (United Kingdom)

DNA damage responses as a barrier to tumourigenesis
Speaker: J. Bartek (Denmark)

The DNA damage response: clues to carcinogenesis - and therapy
Speaker: Y. Shiloh (Israel)

Exploiting cancer defects in targeted therapy
T. Helleday (United Kingdom)

DNA polymerases and cancer
U. Hübscher (Switzerland)

Chromatin remodelling and cancer
Z. Horcég (France)

Growth factors and receptors as oncogenes
W. Gullick (United Kingdom)

RAS (Title to be confirmed)
M. Barbacid (Spain)

The role of mTOR in cancer
S. Faivre (France)

P53: balancing tumor suppression and implications for the clinic
V. Rotter (Israel)

Identification of cancer genes and their collaborative networks by large-scale mutagenesis in tumour prone mice
A. Berns (The Netherlands)

The genetic basis of the concept
L.J. van’t Veer (The Netherlands)

Prognostic implications in breast cancer
C. Caldas (United Kingdom)

Therapeutic approach of early and advanced triple negative breast cancer
Speaker: C. Jackisch (Germany)

Optimising anti-HER2 therapy in early breast cancer
M. Piccart (Belgium)

Anti-HER2 therapy treatment after progression
Speaker: G. von Minckwitz (Germany)

Antiangiogenic drugs - Quo Vadis?
D. Miles (United Kingdom)

Anti-EGFR and anti-angiogenic therapy - from mice to men
K. Lamszus (Germany)

PTEN inhibition as a target
I.K. Mellinghoff (USA)

Novel molecular targets in the clinic
U. Bogdahn (Germany)

Overview of the biomarker problem
D. Sidransky (USA)

The need for robust statistical designs to bring biomarkers to the clinic
R. Simon (USA)

Circulating tumour cells in early clinical trials
J. de Bono (United Kingdom)

Genomics in early clinical trials
L. Pusztai (USA)

Genetic factors in breast cancer
D. Easton (United Kingdom)

Genetic factors in lung cancer
P.J. Brennan (France)

Genomic profiling of colorectal cancer
P.G. Johnston (Ireland)
dMMR: always genetic and sometimes hereditary
N. Hoogerbrugge (The Netherlands)

Should patients with dMMR be treated with chemotherapy?
R. Labianca (Italy)

Hereditary factors in bladder cancer
L.A. Kiemeneij (The Netherlands)

Histopathological profile of bladder cancer
A. Lopez-Beltran (Spain)

Genomic alterations in urothelial carcinoma subgroups
M. Knowles (United Kingdom)

Advances in molecular understanding of prostate cancer
J. Schalken (The Netherlands)

Prostate cancer: the bone paradigm...
B. Tombal (Belgium)

Drug resistance in metastatic PCA
I.F. Tannock (Canada)

Harnessing the immune system for ovarian cancer therapy
G. Coukos (USA)

Clinical trials on immunotherapy in ovarian cancer
H. Nijman (The Netherlands)

Biology of tumour angiogenesis and potential biomarkers of effects
C. Ruegg (Switzerland)

Molecular pathogenesis and biology of secondary leukemias
D. Grimwade (United Kingdom)

Secondary leukemia after breast cancer
F. Lo-Coco (Italy)

Secondary leukemia after Hodgkin’s disease
A. Engert (Germany)

New drugs and novel therapeutic principles in multiple myeloma
J.F. San Miguel (Spain)

Tyrosine kinase inhibitors in myeloid malignancies
A. Burnett (United Kingdom)

JAK-2 and its inhibitors for myeloid neoplasias
A. Tefferi (USA)

HDACs inhibitors for lymphoid neoplasias
M. Kirschbaum (USA)

Novel drugs in CLL
M. Hallek (Germany)

Reporter gene imaging in cancer
R. Blasberg (USA)

Imaging of the tumour microenvironment
R.J. Gillies (USA)

Life and death of the cancer cell-PET imaging of proliferation and apoptosis
Speaker: E. Aboagyé (United Kingdom)

MR imaging of angiogenesis
G. Jayson (United Kingdom)

The role of biomarkers in selecting the right targeted agent to combine with chemotherapy
G. Giaccone (USA)

Molecular mechanisms of lung cancer development - how to use our knowledge of molecular biology in more effective therapies
Y. Yarden (Israel)

Genetic aberrations as determinants of response to chemotherapy
R. Rosell (Spain)

EGF receptors
F. Ciardiello (Italy)

Biology of mesothelioma
P.A. Zucali (Italy)

How to perform translational research in melanoma
A. Spatz (Canada)

Targeting immune checkpoints: CTLA-4 and related molecules
U. Keilholz (Germany)

Melanoma vaccines - quo vadis?
G. Parmiani (Italy)

Targeting VEGF: sorafenib, axitinib, bevacizumab and others
P. Lorigan (United Kingdom)

Novel agents in clinical development (including bcl-2 antisense)
K. Flaherty (USA)

Obesity and overall cancer risk
A.ew.G. Renehan (United Kingdom)

Drug/lifestyle and breast cancer prevention
J. Cuzick (United Kingdom)

Drug/lifestyle and colon cancer prevention
F. Otto (Switzerland)

New approaches to clinical trial design for rare tumours including childhood cancer
M. Le Deley (France)

Leukaemic stem cells and their implications for therapy in childhood leukaemia
E. Jacobsen (United Kingdom)

Genome wide approaches to identify new genetic alteration in childhood leukemia
J.R. Downing (USA)

Tailored treatment of childhood ALL
M. Schrappe (Germany)

Perspectives in cell and gene therapy of childhood leukemia
A. Biondi (Italy)

Changing indications for stem cell transplant in leukaemia in children and young adults
C. Peters (Austria)

The role of randomised trials and surrogate biomarkers in early clinical development
M. Buyse (Belgium)

Integration of diagnostic markers into the development process of targeted agents
R. Simon (USA)

What is new in DNA repair of radiation damage
G. Iliakis (Germany)

How can we utilize DNA repair assays in prediction of radiation response
A. Kittie (United Kingdom)

European tissue and data base infrastructure
K. Haustermans (Belgium)

Low dose cell responses - predictors of normal tissue damage after radiotherapy?
P. O’Neill (UK)

Genetic markers of normal tissue effects after radiotherapy
E. Dikomey (Germany)
Biological imaging in treatment planning
M. Alber (Germany)

Clinical status of bio-imaging for radiotherapy
V. Valentini (Italy)

Functional imaging methods for oncology
N. Sibson (United Kingdom)

Validation of bio-imaging methods for radiotherapy
D. Zips (Germany)

Radioresistance of cancer stem cells
F. Pajonk (USA)

Cancer stem cells as determinant of tumour radioresistance
M. Baumann (Germany)

Targeting the tumour stroma
N. Cordes (Germany)

How to address interlinkage of pathways
H.P. Rodemann (Germany)

Improving radiotherapy by targeting the bone marrow derived stroma
M. Brown (USA)

PI3 kinase
K. Berns (The Netherlands)

An overview of resistance to anti-EGFR/HER2 agents
J. Baselga (Spain)

IGF-I receptor
F.J. Esteva (USA)

DNA replication proteins as biomarkers in cancer
R. Laskey (United Kingdom)

Minichromosome maintenance proteins as markers for cancer screening
N. Coleman (United Kingdom)

Stem Cells and digestive organ cancers
M. Alison (United Kingdom)

Breast cancer stem cells
B. Groner (Germany)

Cancer stem cells in haematological malignancies - implications for understanding pathogenesis and targeted therapy
H.E. Johnsen (Denmark)

Imaging in early drug development-the pharmacology
S. Galbraith (USA)

The RAF-kinase family and cancer
R. Marais (United Kingdom)

Therapeutic strategies for targeting BRAF in human cancer
D. Solit (USA)

The MET oncogene: physiology and pathology of invasive growth
P.M. Comoglio (Italy)

MET inhibitors in cancer therapy
To be announced

Methods for detection of circulating tumour cells: potential & limitations
C. Panabieres (France)

Characterization and monitoring of circulating tumour cells
K. Pantel (Germany)

The prognostic and therapeutic implications of circulating tumour cells in breast cancer
O. Fodstad (Norway)

Novel tool for drug efficacy testing
M. Ignatiadis (Belgium)

The EACR Special Conference on Inflammation and Cancer

Chaired by Claire Lewis, Karin de Visser and Antonio Sica

Keynote Speakers: Lisa Coussens - USA and Alberto Mantovani - Italy

Mariano Barbacid - Spain
Adit Ben-Baruch - Israel
Vincenzo Bronte - Italy
Martin Brown - USA

Peter Carmelet - Belgium
Michele de Palma - Italy
Karin de Visser - Netherlands
Ursula Grohmann - Italy

Randy Johnson - USA
Michael Karin - USA
Toby Lawrence - UK
Claire Lewis - UK

Eli Pikarsky - Israel
Joachim Schultze - Germany
Antonio Sica - Italy
Laurence Zitvogel - France

The EACR Special Conference on ‘Inflammation and Cancer’ will be the first meeting of its kind in Europe. Of interest to basic and translational researchers alike, it will bring an important and rapidly expanding area of cancer research to many cancer researchers in the European community.

The meeting immediately follows the ECCO15/34ESMO Congress in Berlin. Participants may register exclusively for ‘Inflammation and Cancer’ but it is anticipated that many attending the main ECCO/ESMO congress will wish to stay on for the Special Conference.

EACR members will be offered special registration rates and a number of meeting bursaries will be available. An EACR Research Award Lecture and Poster Awards will also be features of this highly focused meeting.

www.eacr.org
Inflammation and Cancer: The Scientific Programme

Keynote Lecture
Lisa M. Coussens,
San Francisco, USA

Symposium: Mouse models of tumour inflammation
Innate-specific immune cell interactions in tumour progression
Karin De Visser,
Amsterdam, The Netherlands

Mouse models of tumour inflammation
Mariano Barbacid,
Madrid, Spain

Myeloid cells, VEGF and tumour growth
Randall S. Johnson,
La Jolla, USA

Awards
EACR Research Award Lecture

Poster Session
Symposium: T cells and Myeloid Dendritic Cells
T cells and Myeloid Dendritic Cells
Joachim L. Schultze,
Cologne, Germany

Myeloid derived suppressor cells
Vincenzo Bronte,
Padua, Italy

Indoleamine 2,3-dioxygenase (IDO) and immunosuppressive mechanisms in tumours
Ursula Grohmann,
Perugia, Italy

Symposium: Inflammation & therapy
Bone marrow-derived cells and responses to radiotherapy
Martin Brown,
Stanford, USA

The resolution of inflammation and cancer
Toby Lawrence,
London, United Kingdom

Toll like Receptors, Dendritic cells and tumour responses to chemotherapy
Laurence Zitvogel,
Villejuif, France

Abstract Submission

Abstracts for the Special Conference must be submitted by e-mail attachment to Davi Kaur, ECCO Scientific Unit Manager: davi.kaur@ecco-org.eu

Abstract submission deadline is 29 April 2009, 09.00 p.m. (21:00 hrs) Central European Time

When submitting your abstract, please indicate if you are willing to be selected to give 'The EACR Researcher Award Lecture' or prefer only to present a poster.

EACR Travel Bursaries

EACR will be making a limited number of bursary awards available for this meeting.

These awards are intended to support the attendance of students or early career researchers who have difficulty in securing funding and would not otherwise be able to participate.

A bursary application form for this meeting can be downloaded from the Meetings page of the EACR website where the Special Conference is advertised http://www.eacr.org/meetings.php

Bursary applications should be submitted with the abstract by e-mail attachment to Davi Kaur, ECCO Scientific Unit Manager: davi.kaur@ecco-org.eu